Diabetic Foot Ulcers Resources

Active diabetic foot disease relates to problems associated with peripheral arterial disease (PAD), infection and/or neuropathy. Diabetes still remains one of the main causes of non-traumatic limb amputation and premature death, both of which may be preventable (Prompers et al, 2007; National Institute for Health and Care Excellence [NICE], 2019). The purpose of this article is to discuss three of the clinical emergencies seen in the diabetic foot, namely PAD, infection and Charcot neuro-osteoarthropathy (Charcot foot). The aim is to provide a refresher of diabetes and the associated complications and to enhance knowledge and clinical skills in the management of diabetic foot disease. A case report is used to provide narrative to the potential complexity seen within the process.

Chronic wounds such as venous leg ulcers and diabetic foot ulcers are increasing in prevalence and impose a significant burden on patients and the NHS alike, particularly if complications related to delayed healing occur, such as infection, cellulitis or amputation. LQD® wound spray is a new primary dressing that contains chitosan FH02™. A multicentre evaluation was carried out across four centres in the UK to determine the efficacy of LQD in promoting wound healing in patients with long-standing venous leg ulcers and diabetic foot ulcers (n=39). The evaluation found that LQD promoted wound healing in almost half of the wounds (n=18), and 15 wounds made significant progress towards healing as measured by reduced wound dimensions and an increase in the healthy wound tissue present. Two wounds remained unchanged. Patients and clinicians reported that the use of LQD had a positive impact on wound progress.